Bibliography
- Duffy MJ , NapieralskiR, MartensJWet al.: Methylated genes as new cancer biomarkers.Eur. J. Cancer45, 335–346 (2009).
- Hayes DF , BastRC, DeschCEet al.: Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.J. Natl Cancer Inst.88, 1456–1466 (1996).
- Harris L , FritscheH, MennelRet al.: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.J. Clin. Oncol.25, 5287–5312 (2007).
- Jänicke F , PrechtlA, ThomssenCet al.: Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.J. Natl Cancer Inst.93, 913–920 (2001).
- Look MP , van PuttenWLJ, DuffyMJet al.: Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.J. Natl Cancer Inst.94, 116–128 (2002).
- Paik S , ShakS, TangGet al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.N. Engl. J. Med.351, 2817–2826 (2004).
- Van’t Veer LJ , DaiH, van de VijverMJet al.: Gene expression profiling predicts clinical outcome of breast cancer.Nature415, 530–536 (2002).
- Wang Y , Klijn, JG, ZhangYet al.: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.Lancet365, 671–679 (2005).
- Ma XJ , HilsenbeckSG, WangWet al.: The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer.J. Clin. Oncol.24, 4611–4619 (2006).
- Sotiriou C , WirapatiP, LoiSet al.: Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.J. Natl Cancer Inst.98, 262–272 (2006).
- Bogaerts J , CardosoF, BuyseMet al.: Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial.Nat. Clin. Pract. Oncol.3, 540–551 (2006).
- Sparano JA : TAILORx: trial assigning individualized options for treatment (Rx).Clin. Breast Cancer7, 347–350 (2006).
- Lo PK , SukumarS: Epigenomics and breast cancer.Pharmacogenomics9, 1879–1902 (2008).
- Esteller M : Epigenetics in cancer.N. Engl. J. Med.358, 1148–1159 (2008).
- Esteller M , FragaMF, GuoMet?al.: DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis.Hum. Mol. Genet.10, 3001–3007 (2001).
- Jones PA : DNA methylation and cancer.Oncogene21, 5358–5360 (2002).
- Baylin SB : DNA methylation and gene silencing in cancer.Nat. Clin. Pract. Oncol.2(Suppl. 1), S4–S11 (2005).
- Bird A : DNA methylation patterns and epigenetic memory.Genes Dev.16, 6–21 (2002).
- Jones PA , BaylinSB: The fundamental role of epigenetic events in cancer.Nat. Rev. Genet.3, 415–428 (2002).
- Knudson AG Jr : Mutation and cancer: statistical study of retinoblastoma.Proc. Natl Acad. Sci. USA68, 820–823 (1971).
- Feinberg AP , VogelsteinB: Hypomethylation distinguishes genes of some human cancers from their normal counterparts.Nature301, 89–92 (1983).
- Lujambio A , RoperoS, BallestarEet al.: Genetic unmasking of an epigenetically silenced microRNA in human cancer cells.Cancer Res.67, 1424–1429 (2007).
- Jones PA , MartienssenR: A blueprint for a Human Epigenome Project: the AACR Human Epigenome Workshop.Cancer Res.65, 11241–11246 (2005).
- Melnikov AA , GartenhausRB, LevensonAS, MotchoulskaiaNA, Levenson ChernokhvostovVV: MSRE-PCR for analysis of gene-specific DNA methylation.Nucleic Acids Res.33, e93 (2005).
- Widschwendter M , FieglH, EgleDet al.: Epigenetic stem cell signature in cancer.Nat. Genet.39, 157–158 (2007).
- Gal-Yam EN , EggerG, IniguezLet al.: Frequent switching of polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line.Proc. Natl Acad. Sci. USA105, 12979–12984 (2008).
- Eads CA , DanenbergKD, KawakamiKet al.: MethyLight: a high-throughput assay to measure DNA methylation.Nucl. Acids Res.28, E32 (2000).
- Uhlmann K , BrinckmannA, ToliatMR, RitterH, NürnbergP: Evaluation of a potential epigenetic biomarker by quantitative methyl-single nucleotide polymorphism analysis.Electrophoresis23, 4072–4079 (2002).
- Mulero-Navarro S , EstellerM: Epigenetic biomarkers for human cancer: the time is now.Crit. Rev. Oncol. Hematol.68, 1–11 (2008).
- Feng W , ShenL, WenSet al.: Correlation between CpG methylation profiles and hormone receptor status in breast cancers.Breast Cancer Res.9, R57 (2007).
- Esteller M : Cancer epigenomics: DNA methylomes and histone-modification maps.Nat. Rev. Genet.8, 286 (2007).
- Locke I , Kote-JaraiZ, FacklerMJet al.: Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controls.Breast Cancer Res.9, R20 (2007).
- Hamilton JP , SatoF, JinZet al.: Reprimo methylation is a potential biomarker of Barrett’s-Associated esophageal neoplastic progression.Clin. Cancer Res.12, 6637–6642 (2006).
- Taylor KH , KramerRS, Davis, JWet al.: Ultradeep bisulfite sequencing analysis of DNA methylation patterns in multiple gene promoters by 454 sequencing.Cancer Res.67, 8511–8518 (2007).
- Maier S , DahlstroemC, HaefligerC, PlumA, PiepenbrockC: Identifying DNA methylation biomarkers of cancer drug response.Am. J. Pharmacogenomics5, 223–232 (2005).
- Chan MW , ChanLW, TangNLet al.: Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients.Clin. Cancer Res.8, 464–470 (2002).
- Rosas SL , KochW, da Costa CarvalhoMGet al.: Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients.Cancer Res.61, 939–942 (2001).
- Ahrendt SA , ChowJT, XuLHet al.: Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer.J. Natl Cancer Inst.91, 332–339 (1999).
- Suh CI , ShanafeltT, MayDJet al.: Comparison of telomerase activity and GSTP1 promoter methylation in ejaculate as potential screening tests for prostate cancer.Mol. Cell. Probes14, 211–217 (2000).
- Rykova EY , TsvetovskayaGA, SergeevaGI, VlassovVV, and LaktionovPP: Methylation-based analysis of circulating DNA for breast tumor screening.Ann. NY Acad. Sci.1137, 232–235 (2008).
- Anker P , MulcahyH, Stroun, M: Circulating nucleic acids in plasma and serum as a noninvasive investigation for cancer: time for large-scale clinical studies?Int. J. Cancer103, 149–152 (2003).
- Fleischhacker, M, SchmidtB: Circulating nucleic acids (CNAs) and cancer – a survey.Biochim. Biophys. Acta1775, 181–232 (2007).
- Levenson VV : Biomarkers for early detection of breast cancer: what, when, and where?Biochim. Biophys. Acta1770, 847–856 (2007).
- Catteau A , MorrisJR: BRCA1 methylation: a significant role in tumor development?Semin. Cancer Biol.12, 359 (2002).
- Esteller M , CornPG, BaylinSB, HermanJG: A gene hypermethylation profile of human cancer.Cancer Res.61, 3225 (2001).
- Umbricht CB , EvronE, GabrielsonE, FergusonA, MarksJ, SukumarS: Hypermethylation of 14-13-3 σ (stratifin) is an early event in breast cancer.Oncogene20, 3348–3353 (2001).
- Hoque MO , FengQ, TourePet al.: Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer.J. Clin. Oncol.24, 4262–4269 (2006).
- Dulaimi E , HillinckJ, de CaceresII, Al-SaleemT, CairnsP: Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.Clin. Cancer Res.10, 6189–6193 (2004).
- Goldhirsch A , IngleJN, GelberRD, CoatesAS, ThurlimannB, SennHJ: Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009.Ann. Oncol.20(8), 1319–1329 (2009).
- Perou CM , SorlieT, EisenMBet al.: Molecular portraits of human breast tumors.Nature406, 747–752 (2000).
- Sorlie T , PerouCM, TibshiraniRet al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.Proc. Natl Acad. Sci. USA98, 10869–10874 (2001).
- Foekens, JA, SieuwertsAM, SmidMet al.: Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer.Proc. Natl Acad. Sci. USA105, 13021–13026 (2008).
- Laird PW : The power and the promise of DNA methylation markers.Nat. Rev. Cancer3, 253–266 (2003).
- Widschwendter M , SiegmundKD, MullerHMet al.: Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen.Cancer Res.64, 3807–3813 (2004).
- Sunami E , ShinozakiM, SimMSet al.: Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors.Breast Cancer Res.10, R46 (2008).
- Schneider BP , WinerEP, FoulkesWDet al.: Triple-negative breast cancer: risk factors to potential targets.Clin. Cancer Res.14, 8010–8018 (2008).
- Lakhani SR , JacquemierJ, Sloane, JPet al.: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.J. Natl Cancer Inst.90, 1138–1145 (1998).
- Birgisdottir V , StefanssonOA, BodvarsdottirSK, HilmarsdottirH, JonassonJG, EyfjordJE: Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.Breast Cancer Res.8, R38 (2006).
- Martens JW , NimmrichI, KoenigTet al.: Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.Cancer Res.65, 4101–4117 (2005).
- Maier S , NimmrichI, KoenigTet al.: DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients – technical and clinical validation in a multicentre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.Eur. J. Cancer43, 1679–1686 (2007).
- Harbeck N , NimmrichI, HartmannAet al.: Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.J. Clin. Oncol.26, 5036–5042 (2008).
- Nimmrich I , SieuwertsAM, Meijer-Van GelderMEet al.: DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.Breast Cancer Res. Treat.111, 429–437 (2008).
- Gennari A , SormaniMP, PronzatoPet al.: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.J. Natl Cancer Inst.100, 14–20 (2008).
- Jones S , HolmesFA, O’ShaughnessyJet al.: Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735.J. Clin. Oncol.27, 1177–1183 (2009).
- Hartmann O , SpyratosF, HarbeckNet al.: DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.Clin. Cancer Res.15, 315–323 (2009).
- Fiegl H , MillingerS, Mueller-HolznerEet al.: Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients.Cancer Res.65, 1141–1145 (2005).
- Zhang JJ , OuyangT, WanWH, DengGR: [Detection of free tumor-related DNA in the serum of breast cancer patients].Zhonghua Zhong Liu Za Zhi,29, 609–613 (2007).
- Brock MV , HookerCM, YungRet al.: Can we improve the cytologic examination of malignant pleural effusions using mlecular analysis?Ann. Thorac. Surg.80, 1241–1247 (2005).